Gilead's (GILD) Sofosbuvir has Favorable Risk-Benefit on HCV

October 23, 2013 8:11 AM EDT
The FDA said Gilead Sciences' (Nasdaq: GILD) Sofosbuvir has a favorable risk-benefit on hepatits C (HCV). From an Antiviral Drugs Advisory Committee Meeting background package submitted today:

The currently available data support a favorable benefit-risk assessment for the use of sofosbuvir as part of a combination regimen for the treatment of chronic hepatitis C. In the HCV GT 2 and 3 populations, the sofosbuvir and ribavirin combination regimen provides the first all-oral, interferon-free treatment, as well as a shorter treatment duration and improved safety profile compared to the current standard of care interferon-based regimen. In addition, SOF+RBV provides a therapeutic option for patients who are ineligible, intolerant or unwilling to take interferon-based regimens, thus addressing an unmet need in this patient population.

The full background package can be accessed here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA